Anacetrapib CEPT inhibition

Description Results NMA

cardiovascular events ∞ [NaN; ∞]

oral anacetrapib 100 mg for 52 weeks (n=204)

vs.

placebo (n=102)

double-blind

Parallel groups

Sample size: 204/102

Primary endpoint: percentage change from baseline in LDL-C

FU duration: 52 weeks

all cause death 1.38 [0.56; 3.40]

Cardiovascular death 4.00 [0.45; 35.76]

Nonfatal stroke 1.00 [0.29; 3.45]

Nonfatal myocardial infarction 0.67 [0.24; 1.87]

Cardiovascular death, myocardial infarction, stroke 0.76 [0.40; 1.45]

cardiovascular events 0.76 [0.40; 1.45]

anacetrapib 100mg fr 18 months (n=811)

vs.

placebo (n=812)

double-blind

Parallel groups

Sample size: 811/812

Primary endpoint: percent change from baseline in LDL cholesterol at 24 weeks

FU duration: